Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder

Phytomedicine

Volumn 19, Issue 8-9, 2012, Pages 665-671

  Uehleke, B ^a,b,c   Schaper, S ^a   Dienel, A ^d   Schlaefke, S ^d   Stange, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b University of Applied Science in Health and Sports   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Clinical trial; Efficacy; Lavender oil; Neurasthenia; Oral administration; Post traumatic stress disorder; Somatization disorder; Sub threshold anxiety

Indexed keywords

HERBACEOUS AGENT; LAVENDER OIL; SILEXAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG EFFICACY; FATIGUE; FEMALE; HERBAL MEDICINE; HUMAN; MALE; NEURASTHENIA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RESTLESSNESS; SHORT FORM 36; SLEEP DISORDER; SOMATIZATION; SYMPTOM CHECKLIST 90; TREATMENT OUTCOME; WAKEFULNESS;

ADMINISTRATION, ORAL; ADULT; AGED; ANXIETY; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURASTHENIA; OILS, VOLATILE; PLANT OILS; PSYCHOMOTOR AGITATION; SLEEP DISORDERS; SOMATOFORM DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

LAVANDULA;

EID: 84861813717     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2012.02.020     Document Type: Article

References (36)

1. S. Akhondzadeh, L. Kashani, A. Fotouhi, S. Jarvandi, M. Mobaseri, M. Moin, M. Khani, H.A. Jamshidi, K. Baghalian, and M. Taghizadeh Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 123 127
2. G.M. Asnis, S.R. Kohn, M. Henderson, and N.L. Brown SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations Drugs 64 2004 383 404
3. B.F. Bradley, S.L. Brown, S. Chu, and R.W. Lea Effects of orally administered lavender essential oil on responses to anxiety-provoking film clips Hum. Psychopharmacol. 24 2009 319 330
4. H.M. Cavanagh, and J.M. Wilkinson Biological activities of lavender essential oil Phytother. Res. 16 2002 301 308
5. L.R. Derogatis Symptom Checklist-90-R: Administrative Scoring and Procedures Manual 1994 NCS Pearson Minneapolis
6. M. Fava, R. Judge, S.L. Hoog, M.E. Nilsson, and S.C. Koke Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment J. Clin. Psychiatry 61 2000 863 867
7. T. Field, M. Diego, M. Hernandez-Reif, W. Cisneros, L. Feijo, Y. Vera, K. Gil, D. Grina, and Q. Claire He Lavender fragrance cleansing gel effects on relaxation Int. J. Neurosci. 115 2005 207 222
8. G.H. Franke Die Symptom-Checkliste von Derogatis - Deutsche Version - Manual 1995 Beltz Test GmbH Göttingen
9. M. Hamilton Hamilton Anxiety Scale (HAMA) W. Guy, ECDEU Assessment Manual for Psychopharmacology 1976 U.S. National Institute of Health, Psychopharmacology Research Branch Rockville, MD 193 197
10. M. Hardy, M.D. Kirk-Smith, and D.D. Stretch Replacement of drug treatment for insomnia by ambient odour Lancet 346 1995 701
11. R.M. Hirschfeld, and L.A. Vornik Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine J. Clin. Psychiatry 65 Suppl. 4 2004 46 52
12. R.M. Hoffmann, T. Müller, G. Hajak, and W. Cassel Abend-Morgenprotokolle in Schlafforschung und Schlafmedizin - Ein Standardinstrument für den deutschsprachigen Raum Somnologie 1 1997 103 109
13. S. Kasper, M. Gastpar, W.E. Müller, H.P. Volz, H.J. Möller, A. Dienel, and S. Schlaefke Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial Int. Clin. Psychopharmacol. 25 2010 277 287
14. P.C. Kendall, A.J. Finch Jr., S.M. Auerbach, J.F. Hooke, and P.J. Mikulka The State-Trait Anxiety Inventory: a systematic evaluation J. Consult. Clin. Psychol. 44 1976 406 412
15. S.C. Knasko Ambient odor's effect on creativity, mood, and perceived health Chem. Senses 17 1992 27 35
16. M. Kritsidima, T. Newton, and K. Asimakopoulou The effects of lavender scent on dental patient anxiety levels: a cluster randomised-controlled trial Commun. Dent. Oral Epidemiol. 38 2010 83 87
17. J. Lehrner, G. Marwinski, S. Lehr, P. Johren, and L. Deecke Ambient odors of orange and lavender reduce anxiety and improve mood in a dental office Physiol. Behav. 86 2005 92 95
18. J.H. Liu, G.H. Chen, H.Z. Yeh, C.K. Huang, and S.K. Poon Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial J. Gastroenterol. 32 1997 765 768
19. M. Louis, and S.D. Kowalski Use of aromatherapy with hospice patients to decrease pain, anxiety, and depression and to promote an increased sense of well-being Am. J. Hosp. Palliat. Care 19 2002 381 386
20. P.S. Masand, and S. Gupta The safety of SSRIs in generalised anxiety disorder: any reason to be anxious? Expert Opin. Drug Saf. 2 2003 485 493
21. C. Maslach, and S.E. Jackson The measurement of experienced burnout J. Occup. Behav. 2 1981 99 113
22. N. Motomura, A. Sakurai, and Y. Yotsuya Reduction of mental stress with lavender odorant Percept. Mot. Skills 93 2001 713 718
23. J.C. Nelson, Y. Lu Pritchett, O. Martynov, J.Y. Yu, C.H. Mallinckrodt, and M.J. Detke The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim. Care Companion J. Clin. Psychiatry 8 2006 212 219
24. S.H. Preskorn Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine J. Clin. Psychiatry 56 Suppl. 6 1995 12 21
25. V. Starcevic Issues in the pharmacological treatment of anxiety disorders Australas. Psychiatry 13 2005 371 374
26. E. Trindade, D. Menon, L.A. Topfer, and C. Coloma Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis Can. Med. Assoc. J. 159 1998 1245 1252
27. B. Uehleke Phytobalneologie Zeitschrift für Phytotherapie 17 1996 26 34
28. E. Vernet-Maury, O. Alaoui-Ismaili, A. Dittmar, G. Delhomme, and J. Chanel Basic emotions induced by odorants: a new approach based on autonomic pattern results J. Auton. Nerv. Syst. 75 1999 176 183
29. H.P. Volz, M. Gastpar, S. Kasper, H.J. Möller, and W.E. Müller Subsyndromale Angststörungen: Definition, Messparameter, Epidemiologie J. Neurol. Neurochir. Psychiatry 12 2011 162 167
30. D. Von Zerssen, F. Strain, and D. Schwarz Evaluation of depressive states, especially in longitudinal studies P. Pichot, R. Olivier-Martin, Psychological Measurements in Psychopharmacology 1974 Karger Basel 189 203
31. J.E. Ware Jr., and C.D. Sherbourne The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection Med. Care 30 1992 473 483
32. G. Weyer Internationale Skalen für Psychiatrie 2004 Hogrefe Göttingen
33. H. Woelk, and S. Schlaefke A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder Phytomedicine 17 2010 94 99
34. N. Wolfe, and J. Herzberg Can aromatherapy oils promote sleep in severely demented patients? Int. J. Geriatr. Psychiatry 11 1996 926 927
35. World Health Organization International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) 1992 World Health Organization Geneva
36. M. Wuchner, and J. Eckert Vergleich von Diagnosegruppen und Klienten verschiedener Kliniken Gruppenpsychotherapie und Gruppendynamik 29 1993 198 214